Angina (Angina Pectoris) Pipeline: 10+ Companies Transforming Chest Pain Management with Novel Cardiovascular Therapies | DelveInsight

The angina therapeutics pipeline is experiencing a renaissance, driven by pharmaceutical companies such as Abbott Laboratories, AstraZeneca, Bayer AG, and Bristol-Myers Squibb. With a focus on improving myocardial efficiency and reducing ischemic burden, emerging therapies-including metabolic modulators, nitric oxide donors, and gene therapies-aim to offer more effective symptom relief and reduce cardiovascular events. Innovations are targeting both stable and microvascular angina forms, addressing the significant unmet needs in chronic angina management and enhancing patients' quality of life.

DelveInsight's "Angina Pectoris Pipeline Insight, 2025" comprehensively analyzes the current clinical landscape and growth prospects in the angina pectoris market. The report covers disease insights, treatment guidelines, and a detailed pipeline assessment from preclinical to marketed stages. It includes drug mechanisms, clinical studies, regulatory progress, and key developments such as collaborations, mergers, funding, and designations.

For emerging angina pectoris drugs, the angina pectoris pipeline analysis report provides a 360° view of the therapeutic landscape by development stage, product type, route of administration, molecule type, and mechanism of action (MOA). The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Explore the full pipeline analysis for angina pectoris and uncover key opportunities @ https://www.delveinsight.com/sample-request/angina-angina-pectoris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Angina Pectoris Pipeline Report
• DelveInsight's angina pectoris pipeline analysis depicts a strong space with 10+ active players working to develop 10+ pipeline drugs for angina pectoris treatment.
• The angina pectoris pipeline is exploring metabolic modulators like ivabradine and ranolazine, which improve myocardial efficiency without affecting heart rate.
• The leading angina pectoris companies include Abbott Laboratories, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan, GlaxoSmithKline, Novartis AG, Pfizer, Sanofi, Xylocor Therapeutics, Imbria Pharmaceuticals, Chong Kun Dang, Caladrius Biosciences, and others are evaluating their lead assets to improve the angina pectoris treatment landscape.
• Key angina pectoris pipeline therapies in various stages of development include XC-001, IMB-101, CKD385, CLBS14, and others.
• Gene therapy trials are focusing on promoting angiogenesis to enhance blood flow and reduce symptoms in patients with refractory angina.
• In January 2024, Lupin Limited received FDA approval for its Abbreviated New Drug Application for Propranolol Hydrochloride Extended-Release Capsules (60 mg, 80 mg, 120 mg, 160 mg), a generic version of Inderal® LA by ANI Pharmaceuticals. Manufactured at Lupin's Pithampur facility in India, the product is indicated for angina pectoris due to coronary atherosclerosis, hypertension, migraine, and hypertrophic subaortic stenosis.

Request a sample and discover the recent breakthroughs happening in the angina pectoris pipeline landscape @ https://www.delveinsight.com/sample-request/angina-angina-pectoris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Angina Pectoris Overview
Angina, also known as angina pectoris, is chest pain or discomfort caused by reduced blood flow to the heart muscle. This condition occurs when the coronary arteries cannot supply enough oxygen-rich blood to meet the heart's demands, often during physical exertion or stress. Coronary heart disease, characterized by the buildup of fatty deposits in the arteries, is the leading cause of angina.

Angina differs from a heart attack as the reduction in blood flow is temporary and does not cause lasting damage to the heart muscle. However, people with angina are at higher risk of a heart attack. There are two main types of angina: Stable angina, which is triggered by specific factors like exertion or stress and lasts 5-15 minutes, and Unstable angina, which lasts longer than 15 minutes and may signal an impending heart attack.

Diagnosis can be confirmed through tests like ECG, stress tests, and coronary angiography. Treatment focuses on relieving symptoms and improving heart health through medications, lifestyle changes, and in some cases, surgery.

Explore top treatments for angina pectoris now @ https://www.delveinsight.com/sample-request/angina-angina-pectoris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Angina Pectoris Treatment Analysis: Drug Profile
CLBS14: Caladrius Biosciences
CLBS14 is part of the CD34+ cell therapy program for NORDA (No-option Refractory Disabling Angina), which affects patients with severe, persistent angina despite revascularization and optimal medical therapy. Clinical studies have shown that a single dose of OLOGOTM reduces mortality, improves angina, and boosts exercise capacity in these patients. This therapy has received FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, allowing for a faster six-month review process for its biologics license application (BLA).

IMB-101: Imbria Pharmaceuticals
IMB-101 is an investigational cardiac mitotrope being developed for cardiovascular disease treatment. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 aims to enhance myocardial metabolic efficiency by shifting substrate utilization toward glucose oxidation, increasing ATP production per unit of oxygen consumed, thus improving energy metabolism in the heart.

XC001: Xylocor Therapeutics
XC001 is an experimental gene therapy designed for patients with refractory angina who have no other treatment options. For those who cannot undergo PCI or coronary bypass surgery, XC001 aims to stimulate the formation of new coronary blood vessels to supply areas of the heart with inadequate blood flow. Based on clinical and pre-clinical evidence, XC001 has the potential to reduce chest pain and improve daily activities. An Investigational New Drug (IND) application is open with the FDA, and a Phase 1/2 trial for refractory angina began in early 2020.

Learn more about the novel and emerging angina pectoris pipeline therapies @ https://www.delveinsight.com/sample-request/angina-angina-pectoris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Angina Pectoris Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

By Molecule Type
• Oligonucleotide
• Peptide
• Small molecule

Scope of the Angina Pectoris Pipeline Report
• Coverage: Global
• Key Angina Pectoris Companies: Abbott Laboratories, AstraZeneca, Bayer AG, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Allergan, GlaxoSmithKline, Novartis AG, Pfizer, Sanofi, Xylocor Therapeutics, Imbria Pharmaceuticals, Chong Kun Dang, Caladrius Biosciences, and others.
• Key Angina Pectoris Pipeline Therapies: XC-001, IMB-101, CKD385, CLBS14, and others.

Dive deep into rich insights for drugs used for angina pectoris treatment; visit @ https://www.delveinsight.com/sample-request/angina-angina-pectoris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Angina Pectoris Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Angina Pectoris Pipeline Therapeutics
6. Angina Pectoris Pipeline: Late-Stage Products (Phase III)
7. Angina Pectoris Pipeline: Mid-Stage Products (Phase II)
8. Angina Pectoris Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.